Kodiak Sciences News

Kodiak Sciences Surges 178% Intraday After Completing Five Phase 3 Trials, FDA Submission Imminent

Kodiak Sciences shares surged 178% intraday after announcing completion of five successful Phase 3 clinical trials, positioning the company to file for FDA approval of its eye disease treatments.

Sep 29, 2026